PARP1 and neoplasm: Its antiproliferative activity in H1299 tumour cells measured as IC50 was 19.92 μM, which was between that of the EGFR inhibitor Gefitinib (IC50 = 6.56 μM) and that of the PARP inhibitor olaparib (IC50 = 35.93 μM).